These are the reasons for these differences of primary antibodies used against PD-L1 (we have used the FDA-approved clone 28-8) or the underlying evaluation criteria (Tumor proportion score (TPS) or combined consideration of carcinoma cells and inflammatory cells (CPS), which we applied, Fig. 4a). Here, CD274 is linked to neoplasm.